^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GnRH antagonist

    Related drugs:
    2d
    to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia (clinicaltrials.gov)
    P3, N=254, Recruiting, JW Pharmaceutical
    New P3 trial
    |
    Yselty (linzagolix)
    20d
    A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (clinicaltrials.gov)
    P3, N=333, Not yet recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
    New P3 trial
    |
    Cetrotide (cetrorelix)
    21d
    A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Firmagon (degarelix)
    22d
    Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial (clinicaltrials.gov)
    P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Orgovyx (relugolix)
    26d
    Insights in Endocervical Mucus Secretion (clinicaltrials.gov)
    P4, N=15, Recruiting, Oregon Health and Science University | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    Orgovyx (relugolix)
    27d
    Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Chr t(15;17)
    |
    cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)
    1m
    Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER) (clinicaltrials.gov)
    P2, N=68, Recruiting, University of Texas Southwestern Medical Center
    New P2 trial
    |
    goserelin acetate • Firmagon (degarelix)
    1m
    Cetrorelix promotes cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer. (PubMed, Front Oncol)
    This mechanism was substantiated by the findings that the PI3K inhibitor LY294002 mimicked cetrorelix's effects without producing an additive apoptotic response, and that GnRHR knockdown abrogated cetrorelix-induced apoptosis, confirming receptor specificity. These findings suggest that cetrorelix may induce EOC apoptosis via the PI3K/AKT-FOXO1 pathway, which provides mechanistic support for the therapeutic potential of GnRH antagonists in EOC management. Moreover, the identified critical regulatory pathways are prospective therapeutic targets for EOC management.
    Journal
    |
    FOXO1 (Forkhead box O1)
    |
    LY294002 • Cetrotide (cetrorelix)
    2ms
    CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=112, Not yet recruiting, Fudan University
    New P2 trial
    |
    docetaxel • abiraterone acetate • triptorelin • goserelin acetate • Firmagon (degarelix)
    2ms
    A Study of HS-10518 in Healthy Adult Premenopausal Females in China (clinicaltrials.gov)
    P1, N=60, Completed, West China Second University Hospital
    New P1 trial
    2ms
    Case Report: Cutaneous metastatic mucin-producing prostate adenocarcinoma. (PubMed, Front Oncol)
    He was started on androgen deprivation therapy with relugolix...It also raises awareness of prostate cancer presenting as solitary cutaneous metastasis and calls attention to the potential value of PSA screening in select elderly patients. Recognizing uncommon cutaneous manifestations may lead to earlier diagnosis and improved management of advanced internal malignancies.
    Journal
    |
    NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8) • NKX3-1 (NK3 homeobox 1)
    |
    Orgovyx (relugolix)
    2ms
    PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov)
    P3, N=504, Completed, Alliance Foundation Trials, LLC. | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jun 2025
    Trial completion • Trial completion date
    |
    abiraterone acetate • prednisone • bicalutamide • apalutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension